Published: 2017-01-02

Elevated C reactive protein levels in obese individuals with metabolic syndromes

Jella Ramdas, Vasantha Jella


Background: C reactive protein (CRP) is a sensitive marker of inflammation. Apart from CRP, obesity is also one of the established risk factor for CVD in adults and children. This study was therefore conducted to assess the association between elevated levels of CRP and obesity.

Methods: 1432 patients, >35 years of age who had come to our hospital for the assessment of risk factors for Cardiovascular disease were included into study. A detailed medical and clinical history was taken from all the patients and BMI was calculated based on the height and weight. Phlebotomy was performed on all patients and blood was collected to test the samples for CRP, LDL cholesterol, HDL cholesterol, triglycerides, fasting blood glucose, uric acid.

Results: The mean age for 1432 patients was 55.3 years. Males had a mean age of 57.2 years and females were 52.9 years. The levels of CRP were within the normal ranges till class I obese individuals. Among the class II and III patients there was an elevated level of CRP. Only about 4.5% of the patients with CRP levels more than 10 mg/l had normal BMI while 42.8% of the patients were under the class III obese BMI.

Conclusions: It was shown in our studies that higher BMI is associated with higher CRP concentrations especially in patients with metabolic syndromes.


C reactive protein, Obesity, Metabolic syndromes

Full Text:



Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54.

Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.

Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring a et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-42.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.

Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-11.

Thompson SG, Kienast J, Pyke SD, , Haverkate F, van de Loo JC. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 2000;332:635-41.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study. Arterioscler Thromb Vasc Biol. 1999;19:3071-8.

Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97:1671-4.

WHO Fact Sheet. Updated in Feb 2015. Available at, Accessed on 20 February, 2016.

Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell.1995;80:15-8.

Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord.1998;22:1145-58.

Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995;80:3052-8.

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin J S et al. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200.

Banks RE, Forbes MA, Storr M, Higginson JE, Thompson D, Raynes JG. The acute phase response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995;102:217-23.

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-37.

World Health Organization Expert Committee. Physical status: the use and interpretation of anthropometry. WHO technical report series No 854 1995. World Health Organization: Geneva.

Executive summary of the third report of the National Cholesterol Education Program (NCEP). expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

Pi-Sunyer FX. Health implications of obesity. Am J Clin Nutr.1991;53:1595S-1603S.

Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ et al. Abdominal adiposity and coronary heart disease in women. JAMA.1998;280:1843-8.

Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African-Americans and whites. Am J Epidemiol. 1998;148:1187-94.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.

Koenig W, Sund M, Frohlich M, Fischer H, Lo¨wel H, Do¨ring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237-42.

Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischaemic heart disease. BMJ. 1996;312:1049-50.

Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-6.

Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-5.

Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Intern J Obes. 2004;28:674-9.

Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study. Circulation. 2000;102:42-7.

Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabet Care. 2000;23:1835-9.

Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-91.

Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.

Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961-7. |

Visser M, Bouter LM, McQuillan M, WeneMH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-5.